<DOC>
	<DOC>NCT00797303</DOC>
	<brief_summary>Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.</brief_summary>
	<brief_title>The Effect of Bevacizumab on Corneal Neovascularization</brief_title>
	<detailed_description>To evaluate the effect of repeated subconjunctival bevacizumab (AvastinÂ®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization. Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.</detailed_description>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Corneal Neovascularization Stable lesion Diabetes Autoimmune diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>cornea</keyword>
	<keyword>neovascularization</keyword>
</DOC>